公开(公告)号：US12121566B2

公开(公告)日：2024-10-22

申请号：US16777625

申请日：2020-01-30

申请人： Horizon Therapeutics USA, Inc.

发明人： Jeffrey D. Kent ,  Brian Lamoreaux

IPC分类号： A61K38/44 ,  A61K9/00 ,  A61K31/52 ,  A61P19/06

CPC分类号： A61K38/44 ,  A61K9/0053 ,  A61K31/52 ,  A61P19/06

摘要： The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and azathioprine immunosuppressive therapy. Also provided are methods of reducing intolerance or enhancing immuno-tolerance to a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and azathioprine immunosuppressive therapy.

公开(公告)号：US20240307412A1

公开(公告)日：2024-09-19

申请号：US18670600

申请日：2024-05-21

申请人： Dyve Biosciences, Inc.

发明人： Ryan Beal

IPC分类号： A61K31/573 ,  A61K9/00 ,  A61K45/06 ,  A61K47/10 ,  A61P19/06

CPC分类号： A61K31/573 ,  A61K9/0014 ,  A61K9/0053 ,  A61K45/06 ,  A61K47/10 ,  A61P19/06

摘要： The present disclosure relates to transdermal formulations, compositions, and methods for treating or preventing inflammation or a symptom thereof, e.g., inflammatory pain.

公开(公告)号：US20240262808A1

公开(公告)日：2024-08-08

申请号：US18557919

申请日：2022-04-28

申请人： JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.

发明人： Dongfang SHI ,  Changjin FU ,  Yan YANG

IPC分类号： C07D403/04 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/4439 ,  A61P19/06 ,  C07D231/56 ,  C07D401/04 ,  C07D405/14 ,  C07D409/04

CPC分类号： C07D403/04 ,  A61K31/416 ,  A61K31/4192 ,  A61K31/4439 ,  A61P19/06 ,  C07D231/56 ,  C07D401/04 ,  C07D405/14 ,  C07D409/04

摘要： It discloses a compound shown in general formula (1) or a pharmaceutically acceptable salt thereof and a method for preparation of the compound; the compound is a xanthine oxidase inhibitor with xanthine oxidase inhibiting activity; the compound has an excellent xanthine oxidase inhibitory activity and has potential application value in anti-gout drugs, anti-hyperuricemia drugs, etc.

公开(公告)号：US20240124409A1

公开(公告)日：2024-04-18

申请号：US18519062

申请日：2023-11-26

申请人： NANJING UNIVERSITY OF CHINESE MEDICINE

发明人： Lihong HU ,  Jian LIU ,  Qi LV ,  Yang HU ,  Dong DONG ,  Ping WANG ,  Meng YANG

IPC分类号： C07D307/93 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00

CPC分类号： C07D307/93 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00

摘要： The present application discloses a class of guaianolide sesquiterpene lactone derivatives and pharmaceutical use thereof. The guaianolide sesquiterpene lactone derivative or a pharmaceutically acceptable salt thereof is shown as general formula I. In the present application, a class of novel guaianolide sesquiterpene lactone derivatives are found by structural optimization with abundant natural ingredients such as parthenolide and dehydrocostus lactone as raw materials, which derivatives have good inhibitory activity on the activation of the NLRP3 inflammasome, and the chemical stability, water solubility and oral bioavailability of which are significantly improved, and it is verified by experiments that the derivatives have inhibitory effects on the activity of the NLRP3 inflammasome and have potential pharmaceutical applications.

公开(公告)号：US20240024385A1

公开(公告)日：2024-01-25

申请号：US17814459

申请日：2022-07-22

申请人： Ningbo Beiyijia Biotechnology Co., Ltd.

发明人： Haifeng LIU ,  Chunyan LI ,  Yanhong LIU ,  Yashan CHEN ,  Fengtao ZHU ,  Hong LIU ,  Tingting PI ,  Qingshan LI

IPC分类号： A61K35/747 ,  A61K47/36 ,  A61K31/519 ,  A61K31/426 ,  A61K31/343 ,  A61K31/192 ,  A61P19/06

CPC分类号： A61K35/747 ,  A61K47/36 ,  A61K31/519 ,  A61K31/426 ,  A61K31/343 ,  A61K31/192 ,  A61P19/06

摘要： Probiotics for the purine-degrading capability under the condition of a rich-nutrient medium are screened, and a culture environment relatively simulating the human intestinal tract is obtained, so that Lactobacillus reuteri strains KLR-1, KLR-3, KLR-4 and KLR-13 are obtained. The probiotic strain or the composition containing the strain has a significant serum uric acid-reducing effect in an animal model. The composition has a probiotic-containing composition and prebiotics. The probiotic-containing composition is one or more of Lactobacillus reuteri, Lactobacillus ferrnenturn, Bacillus coagulans, Lactobacillus rhamnosus, Lactobacillus casei and Lactobacillus plantarum. The prepared compound probiotic powder can significantly reduce the serum uric acid of gout patients and has the effect of dissolving urate crystals.

公开(公告)号：US20230346765A1

公开(公告)日：2023-11-02

申请号：US17905995

申请日：2021-03-03

申请人： Baylor College of Medicine

发明人： Changyi Chen ,  Qizhi Yao ,  Jian-Ming Lu

IPC分类号： A61K31/455 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/11 ,  A61P19/06

CPC分类号： A61K31/455 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/11 ,  A61P19/06

摘要： Provided herein are methods of using niflumic acid and derivatives thereof for treating a disease or condition associated with elevated serum uric levels in a subject. The methods include administering to the subject an effective amount of a pharmaceutical composition as described herein. The disease or condition associated with elevated serum uric levels can include, for example, gout, hyperuricemia, or cardiovascular disease. Also provided herein are methods of reducing serum uric acid levels in a subject and methods for inhibiting xanthine oxidase activity in a cell. Novel pharmaceutical compositions are also provided herein. (I)

公开(公告)号：US11802121B2

公开(公告)日：2023-10-31

申请号：US18049052

申请日：2022-10-24

申请人： Pfizer Inc.

发明人： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  Matthew S. Dowling ,  David Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Gajendra Ingle ,  Wenhua Jiao ,  Chris Limberakis ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC分类号： A61K31/496 ,  A61K31/4545 ,  C07D401/14 ,  C07D487/04 ,  A61P3/00 ,  A61P15/10 ,  A61P17/06 ,  A61P9/10 ,  A61P19/06 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  A61P1/16 ,  A61P25/02 ,  A61P3/04 ,  A61P19/02 ,  A61P3/10 ,  A61P13/12 ,  A61P25/18 ,  A61P1/00 ,  A61P15/00 ,  A61P25/16 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

CPC分类号： C07D401/14 ,  A61K31/4545 ,  A61K31/496 ,  A61P1/00 ,  A61P1/16 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P15/00 ,  A61P15/10 ,  A61P17/06 ,  A61P19/02 ,  A61P19/06 ,  A61P25/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

摘要： Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20230322703A1

公开(公告)日：2023-10-12

申请号：US17766435

申请日：2020-10-30

申请人： MEDSHINE DISCOVERY INC.

发明人： Yang ZHANG ,  Wentao WU ,  Wenyuan ZHU ,  Shuhui CHEN

IPC分类号： C07D495/04 ,  A61P19/06 ,  C07D333/70

CPC分类号： C07D333/70 ,  A61P19/06 ,  C07D495/04

摘要： A class of xanthine oxidase (XO) inhibitors, and application thereof in the preparation of drugs for treating XO-related diseases. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

公开(公告)号：US11512070B2

公开(公告)日：2022-11-29

申请号：US17085534

申请日：2020-10-30

申请人： Pfizer Inc.

发明人： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  Matthew S. Dowling ,  David Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Gajendra Ingle ,  Wenhua Jiao ,  Chris Limberakis ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC分类号： C07D401/14 ,  A61K31/496 ,  A61K31/4545 ,  C07D487/04 ,  A61P3/00 ,  A61P15/10 ,  A61P17/06 ,  A61P9/10 ,  A61P19/06 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  A61P1/16 ,  A61P25/02 ,  A61P3/04 ,  A61P19/02 ,  A61P3/10 ,  A61P13/12 ,  A61P25/18 ,  A61P1/00 ,  A61P15/00 ,  A61P25/16 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

摘要： Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US11446306B2

公开(公告)日：2022-09-20

申请号：US16940785

申请日：2020-07-28

申请人： ZENITH EPIGENETICS LTD.

发明人： John Frederick Quinn ,  Bryan Cordell Duffy ,  Shuang Liu ,  Ruifang Wang ,  May Xiaowu Jiang ,  Gregory Scott Martin ,  Gregory Steven Wagner ,  Peter Ronald Young

IPC分类号： A61K31/5377 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/52 ,  A61K45/06 ,  C07D413/04 ,  C07D471/04 ,  C07D473/34 ,  A61P1/16 ,  A61P11/00 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/18 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P3/12 ,  A61P5/14 ,  A61P5/50 ,  A61P7/04 ,  A61P7/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/14 ,  A61P11/02 ,  A61P11/16 ,  A61P13/10 ,  A61P13/12 ,  A61P15/16 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/06 ,  A61P19/08 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P27/04 ,  A61P27/16 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00

摘要： The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.